A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Sponsor: Microbio Co Ltd
Listed as NCT04909034, this NA trial focuses on NSCLC Stage IIIB~IV and remains completed. Sponsored by Microbio Co Ltd, it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Jan 2025 — Sep 2025 [monthly]
Completed NA
Status: Unknown → Completed · Phase: PHASE2 → NA
-
Sep 2024 — Jan 2025 [monthly]
Unknown PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Nov 2021 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Microbio Co Ltd
For direct contact, visit the study record on ClinicalTrials.gov .